Medical Biochemistry Department, Medicine and Clinical Studies Research Institute, National Research Centre, 33 El-Bohouth st., Dokki, P.O. 12622, Giza, Egypt.
Cancer Biology and Genetics Laboratory, Centre of Excellence for Advanced Sciences, National Research Centre, Giza, Egypt.
J Cancer Res Clin Oncol. 2023 Jul;149(8):5437-5451. doi: 10.1007/s00432-022-04492-2. Epub 2022 Dec 2.
Breast cancer (BC) is one of the most commonly diagnosed solid malignancies in women worldwide.
Finding new non-invasive circulating diagnostic biomarkers will facilitate the early prediction of BC and provide valuable insight into disease progression and response to therapy using a safe and more accessible approach available every inspection time. Therefore, our present study aimed to investigate expression patterns of potentially circulating biomarkers that can differentiate well between benign, malignant, and healthy subjects.
To achieve our target, quantitative analyses were performed for some circulating biomarkers which have a role in the proliferation and tumor growth, as well as, glutamic acid, and human epidermal growth receptor 2 (HER2) in blood samples of BC patients in comparison to healthy controls using qRT-PCR, liquid chromatography/mass spectrometry (LC/MS/MS), and ELISA.
Our findings showed that the two miRNAs (miRNA-145, miRNA-382) were expressed at lower levels in BC sera than healthy control group, while miRNA-21 was expressed at higher levels in BC patients than control subjects. Area under ROC curves of BC samples revealed that AUC of miRNA-145, miRNA-382, miRNA-21, and glutamic acid was evaluated to equal 0.99, 1.00, 1.00 and 1.00, respectively. Besides, there was a significantly positive correlation between miRNA-145 and miRNA-382 (r = 0.737), and a highly significant positive correlation between miRNA-21 and glutamic acid (r = 0.385).
Based on our results, we conclude that the detection of serum miRNA-145, -382 and -21 as a panel along with glutamic acid, and circulating HER2 concentrations could be useful as a non-invasive diagnostic profiling for early prediction of breast cancer in Egyptian patients. It can provide an insight into disease progression, discriminate between malignancy and healthy control, and overcome the use limitations (low sensitivity and specificity, repeated risky exposure, and high cost) of other detecting tools, including mammography, magnetic resonance imaging, and ultrasound.
乳腺癌（BC）是全球女性中最常见的实体恶性肿瘤之一。
寻找新的非侵入性循环诊断生物标志物，将有助于早期预测 BC，并通过使用更安全、更容易获得的方法，为疾病进展和对治疗的反应提供有价值的见解，该方法可在每次检查时使用。因此，本研究旨在探讨潜在的循环生物标志物的表达模式，这些标志物可以很好地区分良性、恶性和健康受试者。
为了实现我们的目标，使用 qRT-PCR、液相色谱/质谱（LC/MS/MS）和 ELISA 对 BC 患者血液样本中的一些循环生物标志物进行定量分析，这些生物标志物在增殖和肿瘤生长中起作用，以及谷氨酸和人表皮生长因子受体 2（HER2）。
我们的研究结果表明，与健康对照组相比，BC 血清中的两种 miRNA（miRNA-145、miRNA-382）表达水平较低，而 miRNA-21 在 BC 患者中的表达水平高于对照组。BC 样本的 ROC 曲线下面积表明，miRNA-145、miRNA-382、miRNA-21 和谷氨酸的 AUC 分别评估为 0.99、1.00、1.00 和 1.00。此外，miRNA-145 和 miRNA-382 之间存在显著正相关（r=0.737），miRNA-21 和谷氨酸之间存在高度显著正相关（r=0.385）。
基于我们的结果，我们得出结论，检测血清 miRNA-145、-382 和 -21 作为一个面板，以及谷氨酸和循环 HER2 浓度，可作为一种非侵入性诊断分析方法，用于早期预测埃及患者的乳腺癌。它可以提供对疾病进展的深入了解，区分恶性肿瘤和健康对照，并克服其他检测工具（包括乳房 X 线照相术、磁共振成像和超声）的使用限制（低灵敏度和特异性、重复危险暴露和高成本）。
